A structured literature review of the direct costs of adult systemic lupus erythematosus in the US

Arthritis Care and Research

Volumn 63, Issue 9, 2011, Pages 1224-1232

  Slawsky, Katherine A ^a   Fernandes, Ancilla W ^c   Fusfeld, Lauren ^b,e   Manzi, Susan ^d   Goss, Thomas F ^b  

^a PatientsLikeMe   (United States)

^b Boston Healthcare Associates Inc   (United States)

^c MEDIMMUNE   (United States)

^d ALLEGHENY HEALTH NETWORK   (United States)

^e Boston Healthcare Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBULATORY CARE; COST BENEFIT ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL DEPARTMENT; HOSPITALIZATION; HUMAN; MEDICAID; NEPHRITIS; OUTPATIENT CARE; PATIENT CARE; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADULT; AMBULATORY CARE; DRUG COSTS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HOSPITAL COSTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MODELS, ECONOMIC; UNITED STATES;

EID: 80052291644     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20502     Document Type: Review

References (31)

1. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS,. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-9. (Pubitemid 37075543)
2. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM,. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56: 2092-4. (Pubitemid 47110409)
3. Balluz L, Philen R, Ortega L, Rosales C, Brock J, Barr D, et al. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am J Epidemiol 2001; 154: 1029-36. (Pubitemid 33121621)
4. Danchenko N, Satia JA, Anthony MS,. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15: 308-18. (Pubitemid 43828810)
5. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS,. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68.
6. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part 1. Arthritis Rheum 2008; 58: 15-25.
7. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205. (Pubitemid 351183308)
8. Kalunian K, Joan TM,. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin 2009; 25: 1501-14.
9. Trager J, Ward M,. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001; 12: 345-51. (Pubitemid 32929862)
10. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23. (Pubitemid 24070529)
11. Doria A,. Lupus: improving long-term prognosis. Lupus 2008; 17: 166-70. (Pubitemid 351588937)
12. Agrawal N, Chiang LK, Rifkin IR,. Lupus nephritis. Semin Nephrol 2006; 26: 95-104. (Pubitemid 43363384)
13. Mok CC,. Prognostic factors in lupus nephritis. Lupus 2005; 14: 39-44. (Pubitemid 40216066)
14. Thorp ML, Eastman L, Smith DH, Johnson ES,. Managing the burden of chronic kidney disease. Dis Manag 2006; 9: 115-21.
15. Lau CS, Mak A,. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009; 5: 400-4.
16. Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009; 51: 66-79.
17. Brunner HI, Sherrard TM, Klein-Gitelman MS,. Cost of treatment of childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006; 55: 184-8.
18. Clarke AE, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. The systemic lupus erythematosus Tri-Nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 2004; 43: 1016-24. (Pubitemid 39144449)
19. Clarke AE, Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008; 47: 329-33. (Pubitemid 351267201)
20. Nichol MB, Shi S, Knight TK, Wallace DJ, Weisman MH,. Eligibility, utilization, and costs in a California Medicaid lupus population. Arthritis Rheum 2004; 51: 996-1003. (Pubitemid 39648194)
21. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ,. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum 2009; 61: 755-63.
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
23. Welch WP, Wade M,. The relative cost of Medicaid enrollees and the commercially insured in HMOs. Health Aff (Millwood) 1995; 14: 212-23.
24. Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 1788-95.
25. Petrou S, Murray L, Cooper P, Davidson LL,. The accuracy of self-reported healthcare resource utilization in health economic studies. Int J Technol Assess Health Care 2002; 18: 705-10.
26. Arnold RG, Kotsanos JG, Motheral B, Ramsey S, Crown W, Puder K, et al. Panel 3: methodological issues in conducting pharmacoeconomic evaluations. Retrospective and claims database studies. Value Health 1999; 2: 82-8.
27. Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J,. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther 2009; 31: 2653-64.
28. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK,. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1159-67.
29. Garris C, Jhingran PM, Engle-Nitz N, Burke J, Wegner J, Dennis G, et al. Cost impact of lupus in a large US managed care health plan [abstract]. Ann Rheum Dis 2010; 69 Suppl: 475.
30. Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. The systemic lupus erythematosus Tri-Nation Study: cumulative indirect costs. Arthritis Rheum 2007; 57: 64-70.
31. McElhone K, Abbott J, Teh LS,. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006; 15: 633-43. (Pubitemid 44682824)